By Rebecca Beyer
Daily Journal Staff Writer
LOS ANGELES - New Jersey-based Merck & Co. is still taking its Vioxx-related litigation one case at a time.
But now, instead of taking them to trial, the drug company plans to take most of its cases to the bargaining table.
The company's decision to pour $4.85 billion into a fund to settle the ma...
Daily Journal Staff Writer
LOS ANGELES - New Jersey-based Merck & Co. is still taking its Vioxx-related litigation one case at a time.
But now, instead of taking them to trial, the drug company plans to take most of its cases to the bargaining table.
The company's decision to pour $4.85 billion into a fund to settle the ma...
To continue reading, please subscribe.
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$795 for an entire year!
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$795 for an entire year!
Or access this article for $45
(Purchase provides 7-day access to this article. Printing, posting or downloading is not allowed.)
Already a subscriber?
Sign In